At a glance
- Originator Pfizer
- Class Antiparkinsonians; Antipsychotics; Neuroprotectants; Small molecules
- Mechanism of Action Antioxidants; Dopamine D2 receptor agonists; Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 14 Feb 2006 No development reported - Preclinical for Parkinson's disease in USA (unspecified route)
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
- 08 Mar 2001 Preclinical development for Parkinson's disease in USA (Unknown route)